1. In Vivo

In Vivo's Deals Of The Month, February 2018

 
• By Nancy Dvorin

In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)

IV_DOTM_1200

Gilead Sciences Inc. will pay up to $3.16 billion for exclusive rights to gene editing pioneer Sangamo Therapeutics Inc.'s zinc finger nuclease technology to help its Kite Pharma Inc. subsidiary create better T cell therapies for cancer. In seeking a partner, Gilead eschewed newer gene editing plays, describing Sangamo's ZFN technology as "the optimal gene editing platform." The partners have identified some initial oncology targets for specific therapeutic programs and will also attempt to develop CAR-T therapies for solid tumors. [See Deal]

mRNA drug developer Moderna Therapeutics LLC added $500 million to its already-full coffers in early February. New investors Abu...

More from Deal-Making

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.